Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/06—Antimalarials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• the present invention relates to novel chemical compounds, tricyclic derivatives and more particularly new heterocyclic derivatives of carbazole, azacarbazole, phenanthridine, phenothazine, phenoxazine and dibenzazepine, the compositions containing them, and their use as medicaments.
• the invention relates to novel heterocyclic derivatives of carbazole, phenanthridine, phenoxazine and dibenzazepine phenothazine having an anticancer activity, and in particular an inhibitory activity of the chaperone protein Hsp90, and more particularly via the inhibition of the ATPase catalytic activity of the Hsp90 chaperone protein.
• HSPs Heat Shock Proteins
• Hsp27, Hsp70, Hsp90 The molecular chaperones of the "Heat Shock Proteins” (HSPs) family, classified according to their molecular mass (Hsp27, Hsp70, Hsp90 ).
• HSPs Heat Shock Proteins
• Hsp90 are key elements of the balance between the synthesis and the degradation of cellular proteins. , responsible for the correct folding of proteins. They play a vital role in response to cellular stress.
• HSPs, and in particular Hsp90 are also involved in the regulation of various major functions of the cell, via their association with various client proteins involved in cell proliferation or apoptosis (JoIIy C. and Morimoto RI, JN Cancer Inst. (2000), 92, 1564-72, Smith DF et al., Pharmacological Rev. (1998), 50, 493-513, Smith DF, Molecular Chaperones in the CeII, 165-178,
• Hsp90 chaperone which accounts for 1-2% of the protein content of the cell, has recently been identified as a particularly promising target in cancer therapy (see for review: Moloney A and Workman P., Expert Opin. Biol. Ther. (2002), 2 (1), 3-24; Chiosis et al, Drug Discovery Today (2004), 9, 881-888).
• This interest is due in particular to the cytoplasmic interactions of Hsp90 with the main Hsp90 client proteins, which are involved in the six mechanisms of tumor progression, as defined by Hanahan D. and Weinberg RA (CeII (2002), 100 , 57-70), namely:
• VEGF-R an ability to activate angiogenesis: VEGF-R, FAK, HIF-1, Akt ...
• Hsp90 steroid hormone receptors such as the estrogen receptor or the androgen receptor also exhibit important interest in the context of anticancer therapies. It has recently been shown that the alpha form of Hsp90 also has an extracellular role via its interaction with the metalloprotease MMP-2, itself involved in tumor invasion (Eustace BK et al., Nature CeII Biology (2004), 6). , 507-514).
• Hsp90 consists of two N- and C-terminal domains separated by a highly charged region. The dynamic interaction between these two domains, coordinated by the fixation of nucleotides and co-chaperones, determines the conformation of the chaperone and its activation state.
• the association of client proteins mainly depends on the nature of the co-chaperones Hsp70 / Hsp40, Hop ⁇ O etc ... and the nature of the ADP or ATP nucleotide linked to the N-terminal domain of Hsp90.
• Hsp90 inhibitors genes coding for "heat-shock proteins" by an Hsp90 inhibitor.
• Alzheimer's Disease and Multiple Sclerosis These diseases are due in part to the expression of pro-inflammatory cytokines and the inducible form of NOS (Nitric oxide synthase) in the brain, and this expression is suppressed by the stress response.
• NOS Nitric oxide synthase
• the Hsp90 inhibitors are capable of garnering this stress response, and it has been shown in vitro that geldanamycin and 17-AAG exhibit anti-inflammatory activity in brain glial cells (J.
• Amyotrophic lateral sclerosis This neurodegenerative disease is due to the progressive loss of motor neurons. Arimoclomol, an inducer of heat-shock proteins, has been shown to delay the course of disease in an animal model (Nature Medicine 10: 402, 2004). Since an Hsp0O inhibitor is also an inducer of heat-shock proteins (Mol., Cell Biol., 19: 8033, 1999; Mol. CeII Biol. 18: 4949, 1998), it is likely that a beneficial effect could be obtained also in this pathology for this type of inhibitors.
• Hsp90 protein could potentially be useful in various diseases, other than the cancer mentioned above, such as parasitic, viral, fungal, or neurodegenerative diseases, by direct action on Hsp90 and special customers.
• diseases other than the cancer mentioned above, such as parasitic, viral, fungal, or neurodegenerative diseases, by direct action on Hsp90 and special customers.
• Some examples are presented below: vi) malaria: Plasmodium falciparum Hsp90 protein
• Toxoplasmosis Toxoplasma gondii, the parasite responsible for toxoplasmosis, has a chaperone protein Hsp90, for which induction has been shown during tachyzoite conversion. bradyzoite, corresponding to transition from chronic infection to active toxoplasmosis.
• Hsp90 chaperone protein
• bradyzoite corresponding to transition from chronic infection to active toxoplasmosis.
• geldanamycin blocks in vitro this tachyzoite-bradyzoite conversion
• Treatment-resistant mycoses It is possible that the Hsp90 protein potentiates the evolution of drug resistance. , allowing new mutations to develop.
• an Hsp90 inhibitor alone or in combination with other antifungal therapy, may be useful in the treatment of some resistant strains (Science 309: 2185, 2005).
• the anti-Hsp90 antibody developed by Neu Tec Pharma demonstrates activity against C. albicans, sensitive and resistant to fluconazole, C. krusei, C. tropicalis, C. glabrata, C. lusitaniae and C. parapsilosis in vivo ( Current Molecular Medicine 5:
• Hepatitis B Hsp90 is one of the host proteins that interacts with hepatitis B virus reverse transcriptase during the replication cycle of the virus. It has been shown that geldanamycin inhibits viral DNA replication and encapsulation of viral RNA (Proc Natl Acad Sci USA 93: 1060, 1996)
• Hepatitis C The human Hsp90 protein participates in the cleavage step between NS2 and NS3 proteins by the viral protease. Geldanamycin and radicicol are able to inhibit this cleavage
• Herpes virus has demonstrated inhibition activities of the replication of HSV-1 virus in vitro, and with a good therapeutic index (Antimicrobial Agents and Chemotherapy 48: 867, 2004). The authors also found geldanamycin activity on other HSV-2, VSV, Cox B3, HIV-1 and SARS coronavirus (data not shown).
• Hsp90 The first known inhibitors of Hsp90 are compounds of the amsamycin family, in particular Geldanamycin (1) and Herbimycin A. X-ray studies have shown that Geldanamycin binds to the ATP site of the N-terminal domain. 'Hsp90 where it inhibits activity
• Radicicol (4) is also a naturally occurring Hsp90 inhibitor (Roe SM et al., J. Med Chem (1999), 42, 260-66). However, if it is by far the best in vitro inhibitor of Hsp90, its metabolic instability towards sulfur nucleophiles makes it difficult to use in vivo. Oxim derivatives much more stable such as KF 55823 (5) or KF 25706 were developed by Kyowa Hakko Kogyo (Soga et al, Cancer Research (1999), 59, 2931-2938) Radioicol (4) (5)
• US2006089495 discloses mixed compounds comprising a quinone ring, such as amsamycin derivatives, and a resorcinol ring such as radicicol analogs, as Hsp90 inhibitors.
• novobiocin 10-10 binds to a different ATP site located in the C-terminal domain of the protein (Itoh H. et al, Biochem J. (1999), 343, 697- 703. Recently, simplified analogues of Novobiocine have been identified as more potent inhibitors of Hsp90 than Novobiocin itself (J. Amer Chem Soc (2005), 127 (37)).
• Patent application WO 2006/050501 claims Novobiocine analogs as Hsp90 inhibitors.
• a depsipeptide, named Pipalamycin or IC1101 has also been described as a noncompetitive inhibitor of the ATP site of Hsp0O (J. Pharmacol Exp Ther (2004), 310, 1288-1295).
• Sherperdine a KHSSGCAFL nonapeptide, mimics a portion of the Survivin sequence K79-K90 (KHSSGCAFLSVK) and blocks the interaction of the IAP family proteins with Hsp90 in vitro (WO 2006014744).
• Small peptides including an Otoferline type sequence (YSLPGYMVKKLLGA), have recently been described as Hsp90 inhibitors (WO2005072766).
• Purines such as PU3 compounds (11) (Chiosis et al., Chem Biol. (2001), 8, 289-299) and PU24FCI (12) (Chiosis et al., Curr Cane Drug
• Hsp90 inhibitors have also been described as Hsp90 inhibitors:
• a purine derivative CNF2024 (13) has recently been introduced clinically by the company Conforma therapeutics, in collaboration with the Sloan Kettering Memorial Institute for Cancer Research (WO 2006/084030).
• Patent application WO2004 / 072080 claims a family of 8-heteroaryl-6-phenylimidazo [1,2-a] pyrazines as modulators of hsp90 activity.
• Patent application WO2005 / 028434 claims aminopurines, aminopyrrolopyrimidines, aminopyrazolopyrimidines and aminotriazolopyrimidines as Hsp90 inhibitors.
• the patent application WO2004 / 050087 claims a family of pyrazoles useful for treating pathologies related to the inhibition of "Heat Shock Proteins" such as the Hsp90 chaperone.
• WO2006 / 018082 claims another family of pyrazoles as Hsp90 inhibitors.
• Patent application WO2005 / 06322 claims a family of resorcinol derivatives as Hsp90 inhibitors.
• Patent application WO2005 / 051808 claims a family of resorcinylbenzoic acid derivatives as Hsp90 inhibitors.
• Proteins' such as the Hsp90 chaperone.
• WO2006 / 010595 claims a family of indazoles as Hsp90 inhibitors.
• WO2006 / 010594 claims a family of dihydrobenzimidazolones as Hsp90 inhibitors.
• Patent application WO2006 / 055760 (Synta Pharma) claims a family of diaryl-triazole as Hsp90 inhibitors.
• Patent application WO2006 / 087077 (Merck) claims a family of (s-triazol-3-yl) phenols as Hsp90 inhibitors.
• Patent application WO2006 / 091963 claims families of tetrahydroindolones and tetrahydroindazolone as Hsp90 inhibitors.
• Patent application WO2006 / 095783 claims a family of triazoles as Hsp90 inhibitors.
• Patent application WO2006101052 claims a family of acetylenic derivatives as Hsp90 inhibitors.
• Patent application WO2006105372 claims a family of alkynyl pyrrolo [2,3-d] pyrimidines as Hsp90 inhibitors.
• Patent application WO2006101052 (Nippon Kayaku) claims a family of acetylenic derivatives as Hsp90 inhibitors.
• Patent application WO2006105372 claims a family of alkynyl pyrrolo [2,3-d] pyrimidines as Hsp90 inhibitors.
• the present invention relates to products of formula (I):
• Het represents an aromatic or partially unsaturated heterocycle - of dihydro or tetrahydro mono or bicyclic type, of 5 to 11 members, containing from 1 to 4 heteroatoms, chosen from NO or S, optionally substituted by one or more radicals R is the same or different as described below, R is in the group consisting of H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio, carboxy free or esterified by a alkyl radical, carboxamide, CO-NH (alkyl) and CON (alkyl) 2, NH-CO-alkyl, NH-SO 2 -alkyl and heterocycloalkyl, all the alkyl, alkoxy, alkylthio and heterocycloalkyl radicals being optionally substituted, R 1 is chosen from the group consisting of X- (AB) n-CONH2,
• R2 and R'2 are independently selected from the group consisting of H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio (methylthio), carboxy free or esterified with an alkyl, carboxamide, CO-NH (alkyl) and NH-CO-alkyl radical, all the alkyl, alkoxy and alkylthio radicals being optionally substituted, p and p ', which are identical or different, respectively represent integers 1 to 4 and 1 to 3;
• L is chosen from a single bond, CH 2, C (O), O, S or NH, said products of formula (I) being in all the possible tautomeric and isomeric forms racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I).
• the present invention relates in particular to the products of formula (I) as defined above in which:
• Het represents a 5- to 10-membered mono or bicyclic heterocycle containing from 1 to 3 heteroatoms selected from N 0 or S, optionally substituted by one or more identical or different radicals R as described below,
• R is in the group consisting of H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, methylthio, carboxy free or esterified with alkyl, carboxamide, CO-NH (alkyl) and CON (alkyl) 2, NH-CO-alkyl, NH-SO 2 -alkyl and heterocycloalkyl, all alkyl, alkoxy, alkylthio and heterocycloalkyl radicals being optionally substituted; R1 is NH- (CH2) 2-O-CONH2; NH- (CH2) 3-O-CONH2; NH- (CH 2) 3 CONH 2; NH- (CH2) 4-CONH2; or
• halogen denotes fluorine, chlorine, bromine or iodine atoms and preferably fluorine, chlorine or bromine atoms.
• alkyl radical denotes a linear or branched radical containing at most 12 carbon atoms chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl and sec-pentyl radicals, tert-pentyl, neo-pentyl, hexyl, isohexyl, sec-hexyl, tert-hexyl and also heptyl, octyl, nonyl, decyl, undecyl and dodecyl, as well as their linear or branched positional isomers.
• alkyl radicals having at most 6 carbon atoms and in particular methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, terbutyl, linear or branched pentyl or linear or branched hexyl radicals.
• alkoxy radical denotes a linear or branched radical containing at most 12 carbon atoms and preferably 6 carbon atoms chosen, for example, from methoxy, ethoxy, propoxy, isopropoxy, linear butoxy, secondary or tertiary, pentoxy, hexoxy and heptoxy radicals; as well as their linear or branched positional isomers,
• alkylthio or alkyl-S- denotes a linear or branched radical containing at most 12 carbon atoms and represents in particular the methylthio, ethylthio, isopropylthio and heptylthio radicals.
• radicals containing a sulfur atom the sulfur atom can be oxidized to an SO or S (O) 2 radical.
• acyl radical or r-CO- denotes a linear or branched radical containing at most 12 carbon atoms in which the radical r represents a hydrogen atom, an alkyl, cycloalkyl, cycloalkenyl, cycloalkyl, heterocycloalkyl or aryl radical, radicals having the values indicated above and being optionally substituted as indicated: mention is made for example of the radicals formyl, acetyl, propionyl, butyryl or benzoyl, or valeryl, hexanoyl, acryloyl, crotonoyl or carbamoyl; the term "cycloalkyl radical” denotes a monocyclic or bicyclic carbocyclic radical containing from 3 to 10 ring members and in particular denotes the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals,
• cycloalkylalkyl radical denotes a radical in which cycloalkyl and alkyl are chosen from the values indicated above: this radical thus designates, for example, the cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl radicals.
• acyloxy radical is meant acyl-O- radicals in which acyl has the meaning indicated above: for example, acetoxy or propionyloxy radicals.
• acylamino radical is meant the acyl-N- radicals in which acyl has the meaning indicated above.
• aryl radical refers to unsaturated, monocyclic or fused carbocyclic ring radicals. Examples of such an aryl radical include phenyl or naphthyl radicals.
• Arylalkyl is understood to mean the radicals resulting from the combination of the alkyl radicals mentioned above which are optionally substituted and the aryl radicals also mentioned above, which are optionally substituted: for example, the benzyl, phenylethyl, 2-phenethyl, triphenylmethyl or naphthyleneemethyl radicals are mentioned.
• heterocyclic radical denotes a saturated (heterocycloalkyl) or partially or completely unsaturated (heteroaryl) carbocyclic radical consisting of 4 to 10 members interrupted by one or more heteroatoms, which may be identical or different, chosen from oxygen, nitrogen or of sulfur.
• heterocycloalkyl radicals mention may be made in particular of the dioxolane, dioxane, dithiolane, thiooxolane, thiooxane, oxiranyl, oxolanyl, dioxolanyl, piperazinyl, piperidyl, pyrrolidinyl, imidazolidinyl, imidazolidine-2,4-dione, pyrazolidinyl or morpholinyl radicals.
• heterocycloalkyl radicals that may be mentioned in particular are the optionally substituted piperazinyl, N-methylpiperazinyl, piperidyl, optionally substituted, optionally substituted pyrrolidinyl, imidazolidinyl, pyrazolidinyl, morpholinyl, hexahydropyran or thioazolidinyl radicals.
• heterocycloalkylalkyl radical is meant radicals in which the heterocycloalkyl and alkyl radicals have the above meanings
• 6-membered heteroaryl radicals such as 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrimidyl, pyridazinyl and pyrazinyl radicals.
• heteroaryl radicals containing at least one heteroatom selected from sulfur, nitrogen and oxygen mention may be made, for example, of benzothienyl, benzofuryl, benzopyrrolyl, benzothiazolyl, benzimidazolyl, imidazopyridyl, purinyl, pyrrolopyrimidinyl, pyrolopyridinyl, benzoxazolyl, benzisoxazolyl and benzisothiazolyl.
• alkylamino radical is meant radicals in which the alkyl radical is chosen from the alkyl radicals mentioned above.
• Alkyl radicals having at most 4 carbon atoms are preferred and mention may be made, for example, of linear or branched, methylamino, ethylamino, propylamino or butylamino radicals.
• dialkylamino radical is meant radicals in which the identical or different alkyl radicals are chosen from the alkyl radicals mentioned above.
• alkyl radicals having at most 4 carbon atoms are preferred, and for example linear or branched dimethylamino, diethylamino or methylethylamino radicals may be mentioned.
• patient refers to humans but also other mammals.
• Prodrug refers to a product that can be converted in vivo by metabolic mechanisms (such as hydrolysis) into a product of formula (I).
• metabolic mechanisms such as hydrolysis
• an ester of a product of formula (I) containing a hydroxyl group can be converted by in vivo hydrolysis to its parent molecule.
• an ester of a product of formula (I) containing a carboxy group can be converted by hydrolysis in vivo into its parent molecule.
• hydroxyl group-containing esters of the formula (I) such as acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene bisulfates and the like.
• b-hydroxynaphthoates gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, camphorsulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.
• Particularly useful hydroxyl-containing products of the formula (I) can be prepared from acidic residues such as those described by Bundgaard et al. al., J. Med. Chem., 1989, 32, page 2503-2507: these esters include, in particular, substituted (aminomethyl) benzoates, dialkylamino-methylbenzoates in which the two alkyl groups may be bonded together or may be interrupted by an oxygen atom or by a optionally substituted nitrogen atom is an alkyl nitrogen atom or else morpholino-methyl) benzoates, eg 3- or 4- (morphomethylomethyl) -benzoates, and (4-alkylpiperazin-1-yl) benzoates, eg 3- or 4- (4-alkylpiperazin-1-yl) benzoates.
• the carboxyl group (s) of the products of formula (I) may be salified or esterified by the various groups known to those skilled in the art, among which may be mentioned, by way of non-limiting examples
• mineral bases such as, for example, one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris (hydroxymethyl) amino methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine , arginine, histidine, N-methylglucamine,
• the alkyl radicals to form alkoxycarbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals being able to be substituted by radicals chosen for example from among the atoms; halogen, hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl groups such as, for example, in chloromethyl, hydroxypropyl, methoxymethyl, propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl or phenethyl groups.
• alkoxycarbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl
• these alkyl radicals being able to be substituted by radicals chosen for example from among the atoms; halogen, hydroxy
• Esterified carboxy is understood to mean, for example, radicals such as alkyloxycarbonyl radicals, for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butyl or tert-butyloxycarbonyl, cyclobutyloxycarbonyl, cyclopentyloxycarbonyl or cyclohexyloxycarbonyl radicals.
• radicals such as alkyloxycarbonyl radicals, for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butyl or tert-butyloxycarbonyl, cyclobutyloxycarbonyl, cyclopentyloxycarbonyl or cyclohexyloxycarbonyl radicals.
• radicals formed with easily cleavable ester residues such as the methoxymethyl and ethoxymethyl radicals; acyloxyalkyl radicals such as pivaloyloxymethyl, pivaloyloxyethyl, acetoxymethyl or acetoxyethyl; alkyloxycarbonyloxyalkyl radicals such as methoxycarbonyloxy methyl or ethyl radicals, isopropyloxycarbonyloxy methyl or ethyl radicals.
• ester radicals can be found, for example, in European Patent EP 0 034 536.
• aminodated carboxy is meant radicals of the -CONH 2 type whose hydrogen atoms are optionally substituted by one or two alkyl radicals to form alkylamino or dialkylamino radicals, themselves optionally substituted as indicated above or below, these radicals may also form with the nitrogen atom to which they are bound a cyclic amine as defined above.
• Salified carboxy means salts formed for example with an equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium. Mention may also be made of salts formed with organic bases such as methylamine, propylamine, trimethylamine, diethylamine and triethylamine. The sodium salt is preferred.
• the addition salts with the inorganic or organic acids of the products of formula (I) can be, for example, the salts formed with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic, acetic, trifluoroacetic, formic acids, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, ascorbic, alkylmonosulphonic acids such as, for example, methanesulfonic acid, ethanesulphonic acid, propanesulphonic acid, alkylsulphonic acids such as, for example, methanedisulfonic acid, alpha, beta-ethanedisulfonic acid, arylmonosulfonic acids such as benzenesulphonic acid and aryldisulphonic acids.
• stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same developed formulas, but whose different groups are arranged differently in space, such as in particular in monosubstituted cyclohexanes whose substituent may be in axial or equatorial position, and the different possible rotational conformations of the ethane derivatives.
• stereoisomerism due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, often called geometric isomerism or cis-trans isomerism.
• stereoisomer is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above.
• the present invention particularly relates to the products of formula (I) as defined in any one of the preceding claims wherein Het is selected from imidazolyl, benzofuranyl, quinolinyl, pyridinyl, indolyl, benzoxazolyl, pyrimidinyl, triazolopyridinyl, benzoxazinyl, quinoxalinyl radicals.
• R 1 represents the radical - NH-C (O) -heteroaryl, with heteroaryl chosen from the quinolyl, pyridyl, purine, quinoxaline, pyrazole, pyrimidinyl, pyrrolo [2,3-b] pyridine, pyrrolo [2,3-c] radicals pyrimidine, imidazo [4,5-b] pyridine, these heteroaryl radicals being optionally substituted with one or more identical or different radicals chosen from halogen atoms, methyl, ethyl, NH 2, Nhalk and NH-Me radicals, R2 and R'2, represent H 1 L represents a single bond or C (O), said products of formula (I) being in all possible tautomeric and isomeric forms racemic, enantiomers and diastereoisomers, as well as addition salts with mineral acids and organic or with the inorganic and organic bases of said products of formula (Ib).
• the present invention thus relates more particularly to
• the present invention particularly relates to the products of formula (I) as defined above whose names follow: - [4- (1H-imidazol-2-yl) -9H-fluorene-9 (R, S) -yl ] 2-Amino-5-chloro-pyrimidine-4-carboxylic acid amide
• the products of formula (I) corresponding to formula (Ia) or (Ib) according to the present invention may be prepared according to methods known to those skilled in the art and particularly according to the methods described below: the present invention thus has also for object the methods of synthesis of the products of formula (Ia) or (Ib) according to the present invention and in particular the general methods of synthesis described in the diagrams below.
• General methods of syntheses of the products of general formula (la) Coupling reaction from a 4-halo-fluoren-9-one: A first general method of synthesis consists in coupling a 9H-4-halo-fluoren-9 -one - such as 9H-4-bromo-fluoren-9-one, which can be obtained according to J. Amer. Chem.
• M Li 1 B (OH) 2 , B (OaIk) 2 , MgHaI 2 , ZnHaI ...
• boronic acid as organometallic heterocycle derivative.
• Coupling reaction from an organometallic derivative of fluoren-9-one-4-yl in a second general method of synthesis, reverse coupling can be envisaged, in particular by using a brominated or iodinated heterocycle and an organometallic derivative of fluoren-9-one, such as 9-oxofluoren-4-boronic acid or one of its esters, according to scheme 2:
• M Li, B (OH) 2 , B (OaIk) 2 , MgHaI 2 , ZnHaI ...
• Heterocycle formation from a fluoren-9-one-4-yl acid or aldehyde derivative in a third general method of synthesis, when said heterocycle is of the benzimidazole, benzoxazole or benzothiazole type, attached to the fluorene derivative by its 2-position, it is particularly advantageous to form said heterocycle by coupling an orthophenylenediamine or ortho-aminophenoid derivative. or orthoaminothiophenol with an acid, an acid chloride or an aldehyde in position 4 of a fluoren-9-one, followed by cyclization, according to scheme 3:
• a fluoren-9-one-4-carboxylic acid When a fluoren-9-one-4-carboxylic acid is used, it is particularly advantageous to activate this acid with a coupling agent known to those skilled in the art, such as hydrochloride of 1 (3-dimethylaminopropyl) -3-ethylcarbodiimide (EDCI) in the presence of 1-hydroxybenzotriazole (HOBT).
• a coupling agent known to those skilled in the art, such as hydrochloride of 1 (3-dimethylaminopropyl) -3-ethylcarbodiimide (EDCI) in the presence of 1-hydroxybenzotriazole (HOBT).
• cyclization conditions of the mixture of intermediate amides can be used in the context of the invention, such as acetic acid or a mixture of acid and trifluoroacetic anhydride. It is also particularly advantageous in the context of the invention to carry out this type of thermal cyclization in an acid medium by heating in a microwave reactor.
• said heterocycle is of the imidazole, oxazole or thiazole type, attached to the fluorene derivative by its 2-position, it is particularly advantageous to form said heterocycle from an acid, an acid chloride of an ester or of an aldehyde in position 4 of a fluoren-9-one, operating according to scheme 4: 1) coupling
• R COOH, COCI, COOaIk, CHO
• any heterocycle from an acid, an acid chloride of an ester or an aldehyde at the 4-d position.
• a fluoren-9-one by any of the synthetic methods known to those skilled in the art, such as those described in Comprehensive Organic Chemistry, by D. Barton et al. (Pergamon Press) or Advances in Heterocyclic Chemistry (Academy Press) or Heterocyclic Compounds (Wiley Intersciences).
• radicals CHR1 as defined in the general formula (Ia) can be carried out according to the general methods known to those skilled in the art, in particular those described in Comprehensive Organic Chemistry, by D. Barton et al. (Pergamon Press), Advanced Organic Chemistry, by J. Marsh (Wiley Interscience), or Compendium of Organic Synthetic Methods (Wiley Interscience).
• a fifth general method of synthesis consists in forming the heterocycle after having previously introduced the CHR1 radical on an acid, an ester, an acid chloride or an aldehyde in position 4 of fluorene ring.
• any heterocycle starting from an acid, an acid chloride of an ester or an aldehyde in position 4 of a fluorene ring substituted in position 9 by a CHR1 radical by any of the synthetic methods known to those skilled in the art, such as those described in Comprehensive Organic Chemistry, by D. Barton et al. (Pergamon Press) or Advances in Heterocyclic Chemistry (Academy Press) or Heterocyclic Compounds (Wiley Intersciences).
• the compounds of general formula (Ib), in which L CO, and for which the heterocycle Het is attached via a nitrogen atom, such as, for example, the heterocycles of the pyrrole, pyrazole, imidazole, indole, isoindole or indazole type.
• benzimidazole or imidazo [4,3-c] pyridine can be advantageously prepared by coupling an anion derived from said heterocycle with a fluoren-9-one-4-carboxylic acid chloride according to scheme 7:
• the products which are the subject of the present invention are endowed with interesting pharmacological properties: they have been found to possess in particular properties inhibiting the activities of chaperone proteins and in particular their ATPase activities.
• the products of formula (I) can also be used in the veterinary field.
• the invention therefore relates to the application, as medicaments, pharmaceutically acceptable products of general formula (I).
• the invention particularly relates to the application as medicaments, products of formula (I) as defined above whose names follow:
• products of formula (I) being in all the possible isomeric forms racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids or with the pharmaceutically acceptable mineral and organic bases of said products of formula (I).
• the products can be administered parenterally, orally, perlingually, rectally or topically.
• the invention also relates to pharmaceutical compositions, characterized in that they contain, as active ingredient, at least one of the drugs of general formula (I).
• compositions may be presented in the form of injectable solutions or suspensions, tablets, coated tablets, capsules, syrups, suppositories, creams, ointments and lotions.
• These pharmaceutical forms are prepared according to the usual methods.
• the active ingredient can be incorporated into excipients usually used in these compositions, such as aqueous vehicles or not, talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, fats of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersing or emulsifying agents, preservatives.
• the usual dose variable depending on the subject treated and the condition in question, can be, for example, from 10 mg to 500 mg per day in humans, orally.
• the present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of medicaments intended to inhibit the activity of chaperone proteins, and especially of Hsp90.
• the present invention thus relates particularly to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the chaperone protein is HSP90.
• the present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicament intended to prevent or treat a disease characterized by the disruption of the activity of a chaperone protein Hsp90 type and in particular such a disease in a mammal.
• the present invention relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicament intended to prevent or treat a disease belonging to the following group neurodegenerative diseases such as Huntington's disease, Parkinson's disease, focal cerebral ischemia, Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis, malaria, Brugia and Bancroft filariasis, toxoplasmosis, treatment-resistant fungi, hepatitis B, hepatitis C, herpes virus, dengue (or tropical flu), spinal and bulbar muscular atrophy, mesangial cell proliferation disorders, thrombosis , retinopathies, psoriasis, muscle degeneration, diseases in oncology, cancers.
• neurodegenerative diseases such as Huntington's disease, Parkinson's disease, focal cerebral ischemia, Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis, malaria, Brugia and
• the present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicament for treating diseases in oncology.
• the present invention particularly relates to the use of products of formula (I) as defined above or pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicament for treating cancers.
• the present invention is particularly interested in the treatment of solid tumors and in the treatment of cancers resistant to cytotoxic agents.
• the present invention thus relates in particular to the use of products of formula (I) as defined in any one of the preceding claims or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicament intended for treating cancers including lung, breast and ovarian cancers, glioblastomas, chronic myeloid leukemias, acute lymphoblastic leukemias, prostate, pancreatic and colon cancers, metastatic melanomas, thyroid tumors and renal carcinomas.
• cancers including lung, breast and ovarian cancers, glioblastomas, chronic myeloid leukemias, acute lymphoblastic leukemias, prostate, pancreatic and colon cancers, metastatic melanomas, thyroid tumors and renal carcinomas.
• Hsp90 inhibitors are also mentioned, without limitation:
• non-small cell lung cancers breast cancers, ovarian cancers and glioblastomas that overexpress EGF-R or HER2;
• the present invention is more particularly concerned with the treatment of breast, colon and lung cancer.
• the present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicament intended for the chemotherapy of cancers.
• the products of formula (I) according to the present invention may be used alone or in combination with chemotherapy or radiotherapy or alternatively in combination with other therapeutic agents.
• the present invention thus relates in particular to pharmaceutical compositions as defined above additionally containing active principles of other cancer chemotherapy drugs.
• Such therapeutic agents may be anti-tumor agents commonly used.
• inhibitors of protein kinases include butyrolactone, flavopiridol, 2- (2-hydroxyethylamino) -6-benzylamino-9-methylpurine, olomucine, Glivec and Iressa.
• the products of formula (I) according to the present invention can thus also advantageously be used in combination with anti-proliferative agents: by way of examples of such anti-proliferative agents but without however being limited to this list, mention may be made of the aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule-active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX inhibitors -2, MMP inhibitors 1 mTOR inhibitors, antineoplastic antimetabolites, platinum compounds, proteasome inhibitors, such as Bortezomib, Histone Decalactylase Inhibitors (HDACs), such as SAHA, including inhibitors HDAC ⁇ , compounds that decrease the activity of protein kinases and also anti-angiogenic compounds, gonadorelin agonists, antiandrogens, bengamides, biphophonates and trastuzumab.
• HDACs
• anti-microtubule agents such as taxoids, epothilones, vinka-alkaloids, alkylating agents such as cyclophosphamide, DNA-intercalating agents such as cis-platinum, and the like.
• oxaliplatin interactive agents on topoisomerase such as camptothecin and derivatives, anthracyclines such as adriamycin, antimetabolites such as 5-fluorouracil and derivatives and the like.
• Step 1 In a 250 ml tricolor, 1.5 g of 2-azidoethylamine, which can be prepared according to Tetrahedron, 47 (38), 1991, 8177-8194, and 3.5 g of sodium chloride are dissolved. fluoren-4-one-9-carboxylic acid in 100 ml of dichloromethane and 4 ml of triethylamine. After stirring for 20 hours at ambient temperature, the reaction medium is poured into water and extracted with dichloromethane. The organic phases are washed with a saturated aqueous solution of sodium hydrogencarbonate and then with water, dried over magnesium sulphate and concentrated under reduced pressure.
• Step 5 In a 100 ml three-necked flask under an argon atmosphere, a solution of 0.65 ml of oxalyl chloride in 5 ml of dichloromethane is cooled to -65 ° C., and 0 94 mL of dimethylsulfoxide on molecular sieve 3A. The mixture is stirred for 10 minutes and then a solution of 1.65 g of trifluoroacetate of toluene is added dropwise. 4- (4,5-dihydro-1H-imidazol-2-yl) -fluoren-9-one acid in 15 ml of dichloromethane and then 5 ml of triethylamine.
• Step 7 The procedure is carried out in an autoclave as in step 3 of Example 5, starting from 449 mg of the equimolecular mixture of the Z and E isomers of 4- (1H-imidazol-2-yl) -fluorene-9- one oxime, obtained in the preceding step, in a mixture of 25 ml of ethanol and 25 ml of tetrahydrofuran, in the presence of activated Nickel according to Raney, under an initial hydrogen pressure of 1 bar, at 60 ° C. for 3 minutes. hours.
• Step 8 The procedure is as in Step 4 of Example 5, starting from 100 mg of 4- (1H-imidazol-2-yl) -9H-fluorene-9 (R, S) -amine, obtained at the previous step, and 74 mg of 2-amino-5-chloro-pyrimidine-4-carboxylic acid in 2 ml of dimethylformamide, in the presence of 116 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride ( EDCI) and 82 mg of 1-hydroxybenzotriazole (HOBT) for 20 hours at room temperature.
• EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
• HOBT 1-hydroxybenzotriazole
• Example 2 Synthesis of [4- (benzofuran-2-yl) -9H-fluoren-9 (R, S) -yl)] - amide of 1H-pyrrolo [2,3-b] pyridine-4 acid carboxylic acid.
• Step 1 In a photochemical reactor containing a 125 W lamp, 5 g of 9-fluorenone-4-carboxylic acid, 22 g of iodobenzene diacetate, 17 g of disubstituted iodine and 450 ml of sodium tetrachloride are introduced successively. carbon. After heating for 20 hours at 78 ° C.
• Step 2 1.2 g of 4-iodofluoren-9-one, obtained in step 1, are dissolved in 30 ml of ethanol in a microwave tube and then 0.52 g are successively added. of bis (triphenylphosphine) palladium (II) chloride, 0.6 g of benzofuran-2-boronic acid and 0.5 ml of triethylamine. After 6 minutes of reaction at 140 ° C., the mixture is concentrated to dryness, the residue is taken up in dichloromethane and with water, the mixture is extracted twice with 20 ml of dichloromethane, dried over sodium sulphate, filtered and concentrated to dryness.
• Step 3 In a tricolor of 100 ml, 0.64 g of 4- (benzofuran-2-yl) -fluoren-9-one, obtained in step 2, are dissolved in 20 ml of ethanol and then added. successively 0.45 g of hydroxylamine hydrochloride and 0.88 g of dry sodium acetate. After stirring overnight at room temperature, it is concentrated to dryness and 20 ml of water are added. The precipitate formed is drained, washed with water and dried under a hood.
• Step 4 In a 100 mL autoclave 0.58 g of equimolar mixture of the 4- and 4-benzofuran-2-yl) -fluoren-9-one isomers Z and E are dissolved in Step 3 in a mixture of 24 ml of ethanol and 24 ml of tetrahydrofuran, an activated nickel spatula tip is added according to
• Step 5 In a tricolor of 25 ml, 400 mg of 4- (benzofuran-2-yl) -9H-fluoren-9 (R, S) -yl) -amine, obtained in step 4, are dissolved in 9 ml. ml of dimethylformamide, then 283 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 90 mg of 1-hydroxybenzotriazole (HOBT) and 218 mg of 1 H-pyrrolo [2 3- b] pyridine-4-carboxylic acid and then stirred for 20 hours at room temperature.
• EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
• HOBT 1-hydroxybenzotriazole
• 1 H-pyrrolo [2 3- b] pyridine-4-carboxylic acid stirred for 20 hours at room temperature.
• Step 1 In a microwavable tube, 1.1 g of 4-iodofluoren-9-one, obtained as in step 1 of Example 2, is dissolved in 25 ml of ethanol and then 0.46 g of (triphenylphosphine) palladium (II) chloride, 0.57 g of quinolin-3-boronic acid and 0.9 ml of triethylamine are added successively. After 8 minutes of reaction at 140 ° C., the mixture is concentrated to dryness, the residue is taken up in dichloromethane and with water, the mixture is extracted twice with 20 ml of dichloromethane, dried over magnesium sulphate, filtered and concentrated to dryness.
• Step 2 In a 50 ml three-necked flask, 0.53 g of 4- (quinoline-3-yl) -fluoren-9-one, obtained in step 1, is dissolved in 15 ml of ethanol and then added. successively 0.36 g of hydroxylamine hydrochloride and 0.7 g of dry sodium. After stirring overnight at room temperature, it is concentrated to dryness and 20 ml of water are added. The precipitate formed is drained, washed with water and dried under a hood.
• Step 3 In a 100 mL autoclave, dissolve 0.51 g of equimolar mixture of the isomers Z and E of 4- (quinolin-3-yl) -fluoren-9-one, obtained in step 2, in a mixture of 20 ml of ethanol and 20 ml of tetrahydrofuran, a tip of Raney-activated nickel spatula is added and then subjected to an initial hydrogen pressure of 1 bar and the autoclave is heated at 60 ° C. for 8 hours. After cooling, the catalyst is filtered through Celite.
• Step 4 In a three-necked 25 mL, 180 mg of [4- (quinolin-3-yl) -9H-fluoren-9 (R, S) -yl] -amine, obtained in step 3, are dissolved in 4 ml of dimethylformamide, then 123 mg of 1 - (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 40 mg of 1-hydroxybenzotriazole (HOBT) and 104 mg of 1 H-pyrrolo [2 , 3-b] pyridine-4-carboxylic acid and then stirred for 20 hours at room temperature.
• EDCI 1 - (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
• HOBT 1-hydroxybenzotriazole
• 1 H-pyrrolo [2 , 3-b] pyridine-4-carboxylic acid stirred for 20 hours at room temperature.
• Example 4 Synthesis of [4- (6-fluoro-pyridin-3-yl) -9H-fluoren-9- (R, S) -yl] -amide of 1H-pyrrolo [2,3-b ] pyridine-4-carboxylic acid.
• Step 1 In a microwavable tube, 0.6 g of 4-lodofluoren-9-one, obtained as in step 1 of Example 2, is dissolved in 12 ml of ethanol, and then 0.28 g of bis (triphenylphosphine) palladium (II) chloride, 0.29 g of 2-fluoropyridin-5-boronic acid and 0.55 ml of triethylamine are added successively.
• Step 3 In a 50 ml autoclave, 0.27 g of equimolar mixture of the Z and E isomers of 4- (6-fluoro-pyridin-3-yl) -fluoren-9-one, obtained by step 2, in a mixture of 10 ml of ethanol and 10 ml of tetrahydrofuran, a Raney-activated nickel spatula tip is added and then subjected to an initial hydrogen pressure of 1 bar and the autoclave is heated to 60.degree. 0 C for 3 hours. After cooling, the concentrate under reduced pressure.
• Step 4 In a tricolor of 25 ml, 230 mg of 4- (6-fluoro-pyridin-3-yl-9H-) -fluoren-9 (R, S) -yl] -amine, obtained by stirring, are dissolved in step 3, in 7 mL of dimethylformamide, then 175 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 57 mg of 1-hydroxybenzotriazole (HOBT) and 149 mg of 1 H-acid are added successively. pyrrolo [2,3-b] pyridine-4-carboxylic acid and then stirred for 20 hours at room temperature.
• EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
• HOBT 1-hydroxybenzotriazole
• Step 1 In a three-necked flask of 100 ml, under an Argon atmosphere, 0.59 g of 4-iodo-fluoren-9-one, obtained as in Step 1 of Example 2, 0.22, are successively introduced. g of palladium (0) tetrakis (triphenylphosphine), 0.6 g of sodium carbonate, 0.5 g of 1- (tert-butoxycarbonyl) -indole-2-boronic acid, 2.8 ml of water and 25 ml of dioxane.
• Step 2 In a 50 ml monocolor, 0.44 g of 2- (9-oxo-9H-fluoren-4-yl) -indole-1-carboxylic acid tert-butyl ester obtained in Step 1 is dissolved. in 10 ml of ethanol, then 0.23 g of hydroxylamine hydrochloride and 0.45 g of dry sodium acetate are successively added. After stirring for 20 hours at room temperature, it is concentrated to dryness and 100 ml of water are added. The precipitate formed is drained, washed with petroleum ether and dried under a hood.
• Step 3 In a 100 ml autoclave, 0.4 g of equimolecular mixture of 2- and 9-oxo-9H-fluoren-4-yl 2-tert-butyl ester isomers Z and E are dissolved.
• 1-indole-1-carboxylic acid, obtained in step 2 in a mixture of 12 ml of ethanol and 12 ml of tetrahydrofuran, a tip of Raney-activated nickel spatula is added and then subjected to an initial pressure of hydrogen of 1 bar and the autoclave is heated at 60 ° C for 8 hours. After cooling, the catalyst is filtered through Celite. The filtrate is concentrated under reduced pressure.
• Step 4 In a three-necked 25 mL, 375 mg of tert-butyl ester of 2- [9 (R, S) -amino-9H-fluoren-4-yl] -1-indole-1-acid are dissolved.
• carboxylic acid obtained in step 3, in 8 mL of dimethylformamide and then added successively 200 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) 1 65 mg of 1- hydroxybenzotriazole (HOBT) and 169 mg of 1 H-pyrrolo [2,3-b] pyridine-4-carboxylic acid and then stirred for 20 hours at room temperature.
• EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
• HOBT 1- hydroxybenzotriazole
• Step 1 In a three-necked 500 ml, 2.5 g of 2-aminophenol are dissolved in 120 ml of dichloromethane, then 2.8 ml of triethylamine and 2.5 g of sodium chloride are successively added at ambient temperature. fluoren-4-one-9-carboxylic acid.
• Step 3 The procedure is as in Step 3 of Example 2, starting from 280 mg of (4-benzoxazol-2-yl) -9H-fluoren-9-one, obtained in the previous step, from 196 mg of mg of hydroxylamine hydrochloride and 386 mg of sodium acetate stirred at room temperature for 48 hours in 12 mL of ethanol. After washing with water and with petroleum ether of the precipitate formed, after filtration and drying, 220 mg of (4-benzoxazol-2-yl) -9H-fluoren-9-one oxime, in a 50-50 mixture, are obtained.
• Z and E isomers in the form of an off-white solid, the characteristics of which are as follows:
• Step 4 In a 50 mL autoclave, 0.22 g of equimolar mixture of the 4- (benzoxazol-2-yl) -fluoren-9-one Z and E isomers, obtained in step 3, are dissolved in a mixture of 12 ml of ethanol and 12 ml of tetrahydrofuran, a tip of Raney-activated nickel spatula is added and then subjected to an initial hydrogen pressure of 1 bar and the autoclave is heated at 60 ° C. for 2 hours. . After cooling, the catalyst is filtered through Celite. The filtrate is concentrated under reduced pressure.
• Step 5 The procedure is as in Step 3 of Example 5 starting from 205 mg of [4- (benzoxazol-2-yl) -9H-fluoren-9- (R, S) -yl] -amine, obtained in step 4, and 123 mg of 1H-pyrrolo [2,3-b] pyridine-4-carboxylic acid, in the presence of 145 mg of EDCI and 47 mg of HOBT, in 6 ml of DMF for 6 hours. The reaction medium is poured into 50 ml of water and the precipitate formed is drained, washed with water, then with a saturated solution of sodium hydrogencarbonate and again with water.
• Example 7 [4- (Pyrimidin-5-yl) -9H-fluoren-9- (R, S) yl] -amide of 1H-pyrrolo [2,3-b] pyridine-4- acid Carboxylic acid
• Step 1 In a microwave tube, 0.5 g of 4-bromo-fluoren-9-one is dissolved, which can be obtained according to J. Amer. Chem. Soc., 57, 2443-6, 1935, in 12 mL of ethanol, then 0.27 g of bis (triphenylphosphine) palladium (II) chloride, 0.25 g of pyrimidino-5-boronic acid and 0.54 mL of triethylamine.
• Step 2 The procedure is as in Step 2 of Example 5, starting from 300 mg of 4- (pyrimidin-5-yl) -fluoren-9-one, obtained in the previous step, of 242 mg of hydroxylamine hydrochloride and 477 mg of sodium acetate stirred at room temperature for 24 hours in 10 ml of ethanol. After concentration of the solvent under reduced pressure, the residue is taken up in water and the precipitate formed is filtered off and then rinsed with pentane.
• Step 3 In a 50 ml autoclave, 0.31 g of equimolecular mixture of 4 (-pyrimidin-5-yl) -fluoren-9-one Z and E isomers, obtained in Step 2, are dissolved in a mixture of 15 ml of ethanol and 15 ml of tetrahydrofuran, a tip of Raney-activated nickel spatula is added and then subjected to an initial hydrogen pressure of 1 bar and the autoclave is heated at 60 ° C. for 2 hours. . After cooling, the catalyst is filtered through Celite. The filtrate is concentrated under reduced pressure. 0.3 g of 4- (pyrimidin-5-yl) -9H-fluoren-9- (R, S) -yl-amine are thus obtained in the form of a brown lacquer, used as such and the characteristic of which is the next one :
• Step 4 The procedure is as in Step 4 of Example 5 starting from 290 mg of 4- (pyrimidin-5-yl) -9H-fluoren-9- (R, S) -yl-amine, obtained at step 4, and 200 mg of 1H-pyrrolo [2,3-b] pyridine-4-carboxylic acid, in the presence of 236 mg of EDCI and 77 mg of HOBT, in 15 mL of DMF for 48 hours.
• the reaction medium is poured into 50 ml of water and the precipitate formed is drained, washed with water, then with a saturated solution of sodium hydrogencarbonate and again with water.
• Example 8 1H-Pyrrolo [2,3-b] pyridine-4-carboxylic acid [4- (quinolin-2-yl) -9H-fluoren-9- (R, S) -yl] -amide Step 1: In a 250 mL tricolor, 2 g
• Step 2 In a 250 ml three-necked flask under Argon atmosphere, 2 g of 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -fluorene are introduced successively. 9-one, obtained in the previous step, 1 g of palladium (0) tetrakis
• Step 3 The procedure is as in Step 2 of Example 5 starting from 940 mg of 4-quinolin-2-yl-fluoren-9-one, obtained in the previous step, of 640 mg of hydroxylamine hydrochloride and 1.25 g of sodium acetate stirred at room temperature for 24 hours in 26 ml of ethanol. After concentration of the solvent under reduced pressure, the residue is taken up in water and the precipitate formed is filtered and then rinsed with pentane. We obtain
• Step 4 In an autoclave of 100 ml, 0.9 g of equimolar mixture of the isomers Z and E of 4- (quinolin-2-yl) -fluoren-9-one oxime, obtained in step 3, are dissolved in A mixture of 40 ml of ethanol and 40 ml of tetrahydrofuran is added with an activated nickel spatula tip.
• Step 5 The procedure is as in Step 4 of Example 5 starting from 200 mg of 4- (quinolin-2-yl) -9H-fluoren-9- (R, S) -yl-amine, obtained at step
• Step 1 In a microwave reactor, 165 mg of 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -fluoren-9-one, obtained with Step 1 of Example 8, 109 mg of palladium (O) tetrakis (triphenylphosphine), 230 mg of cesium carbonate, 93 mg of 2-bromo- [1,2,4] triazolo [1,5-a] ] pyridine in 2 mL of anhydrous dimethylformamide.
• Step 2 The procedure is as in Step 2 of Example 5, starting from 65 mg of 4 - ⁇ [1,2,4] triazolo [1,5-a] pyridin-2-yl ⁇ -fluorene. 9-one, obtained in the preceding step, of 45.6 mg of hydroxylamine hydrochloride and 89.7 mg of sodium acetate stirred at ambient temperature for 2 hours, then at reflux for 9 hours and 30 minutes in 26 mL of ethanol. After concentrating the solvent under reduced pressure, the residue is taken up in water and the precipitate formed is filtered and then dried under vacuum at 50 °.
• Step 3 In a 25 ml three-necked flask, 67 mg of equimolar mixture of the isomers Z and E of 4 - ⁇ [1,2,4] triazolo [1,5-a] pyridin-2-yl ⁇ fluorene are dissolved. 9-one oxime, obtained in step 2, in a mixture of 2 ml of ethanol, 1 ml of acetic acid and 1 ml of water, then 56 mg of zinc are added and the mixture is stirred at room temperature for 1 hour. hour. After filtration of the excess zinc on celite, rinsing with ethanol and concentration to dryness under reduced pressure, the residue is taken up with 50 mL of water.
• Step 4 The procedure is as in Step 4 of Example 5 starting from 48 mg of 4 - ⁇ [1,2,4] triazolo [1,5-a] pyridin-2-yl ⁇ -9H-fluorene (R, S) -yl-amine, obtained in step 3, and 28.7 mg of 1 H-pyrrolo [2,3-b] pyridine-4-carboxylic acid, in the presence of 33 9 mg of EDCI and 12.3 mg of HOBT in 1 mL of DMF for 2 hours.
• the reaction medium is poured into 7 ml of water and the precipitate formed is drained, washed with 10 ml of water and then 3 times with a saturated solution of sodium hydrogencarbonate and then with water.
• Step 1 In a microwave reactor, 410 mg of 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -fluoren-9-one, obtained in accordance with Step 1 of Example 8, 535 mg of palladium (O) tetrakis (triphenylphosphine), 535 mg of cesium carbonate and 555 mg of N-tert-butyloxycarbonyl-3-iodo-1,4-benzoxazine in 10 mL. anhydrous dimethylformamide. After heating for 12 minutes at 140 ° C., it is poured into 60 ml of water and extracted twice with 30 ml of ethyl acetate.
• N-tert-butyloxycarbonyl-3-iodo-1,4-benzoxazine can be obtained by operating according to Tetrahedron Lett. (1998), 39 (32), 5763-4.
• Step 2 Proceed as in Step 2 of Example 5, starting from 374 mg of 4- (N-tert-butyloxycarbonyl-1,4-benzoxazin-3-yl) -fluoren-9-one, obtained in the previous step, 189.5 mg of hydroxylamine hydrochloride and 373 mg of sodium acetate stirred at room temperature for 3 days in 15 mL of ethanol. After concentration of the solvent under reduced pressure, the residue is taken up in water; the precipitate formed is drained, washed with petroleum ether and then dried in air.
• Step 3 In a three-necked mixture of 25 ml, 190 mg of equimolar mixture of isomers Z and E of 4- (N-tert-butyloxycarbonyl-1,4-benzoxazin-3-yl) -fluoren-9-one oxime are dissolved, obtained in step 2, in a mixture of 4 mL of ethanol, 2 mL of acetic acid and 2 mL of water, then 116.5 mg of zinc are added and stirred at room temperature for 2 hours. After filtration of excess zinc on Celite, rinsed with dichloromethane and then with ethanol, concentrated to dryness under reduced pressure.
• Example 12 1H-Pyrrolo [2,3-b] pyridine-4-carboxylic acid [4- (quinoxalin-2-yl) -9H-fluoren-9 (R, S) -yl] -amide
• Step 1 In a microwave reactor, 284 mg of 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -fluoren-9-one, successively introduced into Step 1 of Example 8, 280 mg of palladium (O) tetrakis (triphenylphosphine), 443.5 mg of cesium carbonate and 150 mg of 2-chloroquinoxaline in 5 mL of anhydrous dimethylformamide. After heating for 30 minutes at 140 ° C., it is poured into 60 ml of water and extracted twice with 30 ml of ethyl acetate.
• Step 2 The procedure is as in Step 3 of Example 2, starting from 170 mg of 4- (quinoxalin-2-yl) -fluoren-9-one, obtained in the previous step, of 115 mg of hydroxylamine hydrochloride and 226 mg of sodium acetate, stirred at room temperature for 20 hours, then at reflux for 3 hours in 8 ml of ethanol. After concentration of the solvent under reduced pressure, the residue is taken up in water; the precipitate formed is filtered, washed with petroleum ether and then dried in air.
• Step 3 In a three-necked 25 ml, 175 mg of equimolar mixture of the isomers Z and E of 4- (quinoxalin-2-yl) fluoren-9-one oxime, obtained in step 2, are dissolved in a mixture of 2.5 ml of ethanol, 2.5 ml of acetic acid and 5 ml of water, then 141.5 mg of zinc are added and the mixture is stirred at ambient temperature for 5 hours. After filtration of the excess zinc on Celite, rinsing with ethanol, 20 ml of a 7N solution of ammonia in methanol are added and concentrated to dryness under reduced pressure.
• Step 4 The procedure is as in Step 4 of Example 5 starting from 30 mg of 4- (quinoxalin-2-yl) -9H-fluoren-9- (R, S) -yl-amine, obtained at step 3, and 17.3 mg of 1 H-pyrrolo [2,3-b] pyridine-4-carboxylic acid, in the presence of 20.4 mg of EDCI and 6.6 mg of HOBT in 1 mL of DMF for 7 hours.
• the reaction medium is poured into 7 ml of water and the precipitate formed is drained, washed with 10 ml of water and then 3 times with a saturated solution of sodium hydrogencarbonate and then with water.
• Example 13 6- [6- (3-bromo-3H-imidazo [4,5-b] pyridine-7 [4- (quinolin-3-yl) -9H-fluoren-9 (R, S) -yl] -amide as in Step 4 of Example 5 starting from 400 mg of
• Step 1 In a tricolor of 50 ml, 864 mg of 4-bromo-fluoren-9-one are successively introduced, which can be obtained according to J. Amer. Chem. Soc. 57, 2443-6 (1935), 1 g of 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -2-morpholino-pyridine, 773 mg of palladium (0). tetrakis (triphenylphosphine) and 1.63 g of cesium carbonate in 21 ml of anhydrous dimethylformamide. After heating for 20 hours at 120 ° C., poured into 25 ml of water and extracted twice with 30 ml of ethyl acetate.
• Step 2 The procedure is as in Step 3 of Example 2, starting from 1 g 4- (2-morpholino-pyridin-5-yl) -fluoren-9-one, obtained in the previous step, from 609 mg of hydroxylamine hydrochloride and 1.18 g of sodium acetate, stirred at room temperature for 20 hours in 27 ml of ethanol. After concentration of the solvent under reduced pressure, the residue is taken up in water; the precipitate formed is filtered, washed with pentane and then dried in air.
• Step 3 In a 100 ml autoclave, 1 g of equimolar mixture of the Z and E isomers of 4- (2-morpholino-pyridin-5-yl) -fluoren-9-one oxime, obtained in step 2, are dissolved. in a mixture of 25 ml of ethanol and 25 ml of tetrahydrofyran, then 175 mg of Raney nickel are added and stirred under a pressure of 1 bar of hydrogen for 10 hours at 60 ° C. After filtration and washing with the ethanol of the catalyst is concentrated to dryness under reduced pressure. The crude solid obtained is purified by mashing in diisopropyl ether.
• Step 4 The procedure is as in Step 4 of Example 5 starting from 343 mg of 4- (2-morpholino-pyridin-5-yl) fluoren-9 (R, S) -yl-amine, obtained at step 3, and 162 mg of 1 H-pyrrolo [2,3-b] pyridine-4-carboxylic acid, in the presence of 211 mg of EDCI and 148.6 mg of HOBT, in 10 ml of DMF for 20 hours. The reaction medium is poured into 7 ml of water and the precipitate formed is drained, washed with 10 ml of water and then 3 times with a saturated solution of sodium hydrogencarbonate and then with water.
• Example 15 [4- (quinolin-3-yl) -9H-fluoren-9 (R, S) -yl] -amide of 2-amino-5-chloropyrimidine-4-carboxylic acid The procedure is as in Step 4 of Example 5 from 308 mg of
• the crude product is purified successively by flash chromatography on 25 g of silica gel (20-40 ⁇ m), eluting with a mixture of dichloromethane and methanol (97.5-2.5 by volume), then HPLC on a 10 ⁇ M Kromasil C18 column (35 cm long, 8 cm in diameter) in the course of stirring with a mixture of water, containing 0.1% trifluoroacetic acid, and acetonitrile (65/35 by volume).
• Step 1 In a 50 ml three-necked flask under argon, 243.4 mg of indazole are dissolved in 10 ml of anhydrous dimethylformamide, then 99 mg of sodium hydride are added in portions and the mixture is stirred for 30 minutes. until complete dissolution. A solution of 500 mg of fluoren-9-one-4-carboxylic acid chloride in 7 ml of dimethylformamide is then added. After stirring for 1 hour and 30 minutes at ambient temperature, the mixture is heated for 1 hour at 70 ° C., and the stirring is then maintained for 1 night. Poured onto 100 mL of water, the precipitate formed is filtered off and washed with petroleum ether and dried in air. 385 mg of 4- (indazole-1-carbonyl) fluoren-9-one are thus obtained in the form of a yellow solid, the characteristic of which is as follows:
• Step 2 The procedure is as in Step 3 of Example 2, starting from 385 mg of 4- (indazole-1-carbonyl) -fluoren-9-one, obtained in the previous step, of 318 mg of hydroxylamine hydrochloride and 318 mg of sodium acetate, stirred at room temperature for 3 hours, then at reflux for 1 hour in 20 ml of ethanol. After concentration of the solvent under reduced pressure, the residue is taken up in water; the precipitate formed is filtered, washed with petroleum ether and then dried in air.
• Step 3 In a three-necked 25 ml, 360 mg of equimolar mixture of isomers Z and E of 4- (indazole-1-carbonyl) -fluoren-9-one oxime, obtained in step 2, are dissolved in a 9.5 mL mixture of ethanol, 4.5 mL of acetic acid and 4.5 ml of water, then 277.5 mg of zinc are added and stirred at room temperature for 1 hour and 30 minutes. After filtration of the excess zinc on celite, rinsing with ethanol, 20 ml of a 7N solution of ammonia in methanol and concentrated to dryness under reduced pressure.
• Step 4 The procedure is as in Step 4 of Example 5 starting from 235 mg of 4- (indazole-1-carbonyl) -fluoren-9 (R, S) -yl-amine, obtained in step 3, and 128.8 mg of 1 H-pyrrolo [2,3-b] pyridine-4-carboxylic acid, in the presence of 152.2 mg of EDCI and 49.8 mg of HOBT, in ml of DMF for 1 night.
• the reaction medium is poured into 7 ml of water and the precipitate formed is drained, washed with 10 ml of water and then 3 times with a saturated solution of sodium hydrogencarbonate and then with water.
• Example 17 [4- (1H-Pyrrolo [2,3-b] pyridin-5-yl) -9H-fluoren-9 (R, S) -yl] -amide of 1H-pyrrolo [2 acid, 3-b] pyridine-4-carboxylic acid
• Step 1 In a tricolor of 50 ml, 1. 062 g of 4-bromo-fluoren-9-one, which can be obtained according to J. Amer, are successively introduced. Chem. Soc. 57, 2443-6 (1935), 1 g of 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-pyrrolo [2,3-b] pyridine 947 mg of palladium (O) tetrakis (triphenylphosphine) and 2.003 g of cesium carbonate in 32 mL of anhydrous dimethylformamide.
• the dimethylformamide is concentrated under reduced pressure and then poured into 25 ml of water, and the mixture is extracted twice with 30 ml of ethyl acetate. After drying over magnesium sulphate and concentration under reduced pressure, the crude solid obtained is purified by flash chromatography on 100 g of silica gel (40-60 ⁇ m), eluting with cyclohexane and then with a mixture of cyclohexane and cyclohexane. ethyl acetate (70-30 by volume).
• Step 2 Proceed as in Step 3 of Example 2, starting from 450 g 4- (1 H -pyrrolo [2,3-b] pyridin-5-yl) -fluoren-9-one, obtained in the previous step, 317 mg of hydroxylamine hydrochloride and 623 mg of sodium acetate, stirred at room temperature for 20 hours in 14 mL of ethanol. After concentration of the solvent under reduced pressure, the residue is taken up in water; the precipitate formed is filtered off, washed with a saturated solution of sodium hydrogencarbonate and then with pentane and then dried in air.
• Step 3 In a 100 ml autoclave, 450 mg of equimolar mixture of the Z- and E-isomers of 4- (1H-pyrrolo [2,3-b] pyridin-5-yl) -fluoren-9-one oxime is dissolved. obtained in step 2, in a mixture of 12 ml of ethanol and 12 ml of tetrahydrofyran, then 90 mg of Raney nickel are added and stirred under a pressure of 1 bar of hydrogen for 10 hours at 60 ° C. C. After filtering and washing with ethanol the catalyst is concentrated to dryness under reduced pressure. The crude solid obtained is purified by mashing in diisopropyl ether.
• Step 4 The procedure is as in Step 4 of Example 5 starting from 400 mg of 4- (1H-pyrrolo [2,3-b] pyridin-5-yl) -fluoren-9 (R, S). ) -yl-amine, obtained in step 3, and 218 mg of 1 H-pyrrolo [2,3-b] pyridine-4-carboxylic acid, in the presence of 284 mg of EDCI and 200 mg of HOBT in 13.5 mL of DMF for 20 hours. The reaction medium is poured into 7 ml of water and the precipitate formed is drained, washed with 10 ml of water and then 3 times with a saturated solution of sodium hydrogencarbonate and then with water.
• Step 1 In a microwave reactor, 916 mg of 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -fluoren-9-one, obtained as in Step 1 of Example 8, 671 mg of palladium (O) tetrakis (triphenylphosphine), 1.42 g of cesium carbonate and 1 g of N8-pivaloyl-3-iodo-5,6,7,8 -tetrahydro-1,8-naphthyridine in 20 ml of anhydrous dimethylformamide. After heating for 20 hours at 120 ° C., it is poured into 60 ml of water and extracted twice with 30 ml of ethyl acetate.
• the crude solid obtained is purified by flash chromatography on 100 g of silica gel (40-60 ⁇ m), eluting with cyclohexane and then with a mixture of cyclohexane and cyclohexane. ethyl acetate (70-30 by volume).
• Step 2 The procedure is as in Step 3 of Example 2, starting from 950 mg of 4- (N8) -pivaloyl-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl) -fluoren-9-one, obtained in the previous step, of 500 mg of hydroxylamine hydrochloride and 983 mg of sodium acetate, stirred at ambient temperature for 20 hours, then under reflux for 3 hours in 22 ml of ethanol.
• Step 3 In a 250 ml autoclave, 750 mg equimolar mixture of the isomers Z and E of 4- (5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl) -fluoren-9 are dissolved. -one oxime, obtained in step 2, in a mixture of 23 ml of ethanol and 23 ml of tetrahydrofyran, then 143 mg of Raney nickel are added and stirred under a pressure of 1 bar of hydrogen for 8 hours at 60 ° C. After filtration and washing with ethanol of the catalyst, it is concentrated to dryness under reduced pressure.
• Step 4 The procedure is as in Step 4 of Example 5 starting from 700 mg of 4- (5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl) -fluoren-9 ( R, S) -yl-amine, obtained in step 3, and 362 mg of 1 H-pyrrolo [2,3-b] pyridine-4-carboxylic acid, in the presence of 471 mg of EDCI and of 332 mg of HOBT in 23 mL of DMF for 20 hours. The reaction medium is poured into 7 ml of water and the precipitate formed is drained, washed with 10 ml of water and then 3 times with a saturated solution of sodium hydrogencarbonate and then with water.
• Example 19 4- ⁇ Imidazo [1,2-a] pyridin-2-yl ⁇ -9H-fluoren-9- (R, S) -yl-amide of 1H-pyrrolo [2,3-b] acid ] pyridine-4-carboxylic acid
• Step 1 In a 1 L flask containing 30 g of monochloroacetic acid dissolved in 150 mL of distilled water, 24.1 g of potassium carbonate are added in small portions. After stirring for 15 minutes after the end of this addition (end of the effervescence), 30 g of 2-aminopyridine are added and the reaction mixture is refluxed for 6 hours. It is allowed to warm to room temperature overnight. The pinkish suspension is filtered, the solid is washed with distilled water and then dried under vacuum at 40 ° C. 15 g of a beige solid of 2-hydroxy-imidazo [1,2-a] pyridine are obtained.
• Step 2 In a 500 ml flask containing 1 g of 2-hydroxy-imidazo [1,2-a] pyridine obtained in the preceding step and 60 ml of toluene, 2.6 g of N-phenylbis (trifluoromethanesulfonimide) are added. and 1 mL of triethylamine and then heated to reflux. After 2 hours and 4 hours of reflux, 2.5 ml and 5 ml of triethylamine are added respectively, and the refluxing is continued for 8 hours. After cooling, 50 ml of distilled water are added, decanted and the aqueous phase is re-extracted with 3 times 50 ml of ethyl acetate.
• N-phenylbis trifluoromethanesulfonimide
• Step 3 In a 100 ml flask, a mixture of 178 mg of 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) fluorene is heated under argon at 120 ° C. 9-one, obtained in step 1 of Example 8, 150 mg of 2-trifluoromethanesulfonyloxy-imidazo [1,2-a] pyridine obtained in step above, 130 mg of palladium (O) tetrakis (triphenylphosphine), 276 mg of cesium carbonate in 20 mL of anhydrous dimethylformamide for 3 hours.
• 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) fluorene is heated under argon at 120 ° C. 9-one, obtained in step 1 of Example 8, 150 mg of 2-trifluoromethanesulfonyloxy-imidazo [1,2-a] pyridine obtained in step above, 130 mg of palla
• Step 4 120 mg of 4- ⁇ imidazo [1,2-a] pyridin-2-yl ⁇ -fluoren-9-one obtained in the previous step are stirred under argon at room temperature under 120 ml of argon at room temperature. 84 mg of hydroxylamine hydrochloride and 160 mg of sodium acetate in 5 mL of ethanol. The reaction medium is evaporated to dryness under vacuum. The residue is taken up in 10 ml of distilled water and the precipitate is filtered, washed with 3 times 1.5 ml of distilled water, twice 1.5 ml of a saturated solution of sodium bicarbonate, 3 times 1, 5 mL of distilled water and dried under vacuum.
• the residue is taken up in 15 ml of distilled water and extracted with 3 times 15 ml of ethyl acetate. The combined organic phases are washed with 10 ml of saturated sodium bicarbonate solution, 2 times 10 ml of distilled water, 10 ml of saturated sodium chloride solution and dried over magnesium sulfate. After evaporation to dryness under vacuum, the residue is chromatographed on silica gel (40-63 ⁇ m), eluting with a mixture of dichloromethane-ethanol (92.5: 7.5).
• Example 22 pharmaceutical composition:
• Excipient for a tablet finished at 1 g (details of the excipient: lactose, talc, starch, magnesium stearate).
• the present invention also includes all the pharmacological compositions prepared with any product of formula (I) according to the present invention.
• the inorganic phosphate released during the hydrolysis of ATP by the ATPase activity of Hsp82 is quantified by the green malachite method.
• this reagent there is formation of the inorganic phosphate-molybdate-malachite green complex which absorbs at a wavelength of 620 nm.
• the products to be evaluated are incubated in a reaction volume of 30 ⁇ l, in the presence of 1 ⁇ M Hsp82 and 250 ⁇ M substrate (ATP) in a buffer composed of 50 mM Hepes-NaOH (pH 7.5), 1 mM DTT, 5 mM MgCl 2 and 50 mM KCl at 37 ° C. for 60 min.
• a range of inorganic phosphate of between 1 and 40 ⁇ M is formed in the same buffer.
• the ATPase activity is then revealed by the addition of 60 .mu.l of the reagent biomol green (Tebu). After 20 min of incubation at room temperature, the absorbance of the different wells is measured using a microplate reader at 620 nm. The inorganic phosphate concentration of each sample is then calculated from the calibration curve.
• the ATPase activity of Hsp82 is expressed as the concentration of inorganic phosphate produced in 60 min.
• the effect of the various products tested is expressed as a percentage inhibition of ATPase activity.
• the compound AOO0187458 has a 50% inhibitory concentration (IC 50) equal to 2.5 ⁇ M
• PK pyruvate kinase
• LDH lactate dehydrogenase
• the decrease in NADH concentration as measured by the decrease in absorbance at the wavelength of 340 nm is proportional to the concentration of ADP produced by HSP82.
• the tested products are incubated in a reaction volume of 100 ⁇ l of buffer composed of 100 mM Hepes-NaOH (pH 7.5), 5 mM MgCl 2, 1 mM DTT, 150 mM KCl, 0.3 mM NADH, 2.5 mM PEP and 250 ⁇ M ATP. This mixture is preincubated at 37 ° C. for 30 min before addition of 3.77 units of LDH and 3.77 units of PK.
• the reaction is initiated by adding the product to be evaluated, in varying concentrations, and Hsp82, at a concentration of 1 ⁇ M.
• the measurement of the enzymatic activity of Hsp82 is then carried out continuously in a microplate reader at 37 ° C. at the wavelength of 340 nm.
• the initial speed of the reaction is obtained by measuring the slope of the tangent at the origin of the recorded curve.
• the enzymatic activity is expressed in ⁇ M of ADP formed per minute.
• the effect of the various products tested is expressed as percentage inhibition of ATPase activity according to the coding below: A: IC50 ⁇ 1 ⁇ M B: 1 ⁇ M ⁇ IC50 ⁇ 10 ⁇ M C: 10 ⁇ M ⁇ IC50 ⁇ 100 ⁇ M Result Table

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Psychiatry (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Molecular Biology (AREA)
• Psychology (AREA)
• Vascular Medicine (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Urology & Nephrology (AREA)
• Biotechnology (AREA)
• Ophthalmology & Optometry (AREA)
• Hospice & Palliative Care (AREA)
• Pain & Pain Management (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Dermatology (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=38069221

Family Applications (1)

Country Status (23)

Cited By (1)

Families Citing this family (6)

Citations (43)

Family Cites Families (6)

• 2006
  • 2006-10-24 FR FR0609331A patent/FR2907453B1/fr not_active Expired - Fee Related
• 2007
  • 2007-10-17 EA EA200970400A patent/EA200970400A1/ru unknown
  • 2007-10-17 AU AU2007310767A patent/AU2007310767A1/en not_active Abandoned
  • 2007-10-17 MX MX2009004049A patent/MX2009004049A/es not_active Application Discontinuation
  • 2007-10-17 CN CNA2007800397476A patent/CN101528735A/zh active Pending
  • 2007-10-17 BR BRPI0718202-3A patent/BRPI0718202A2/pt not_active Application Discontinuation
  • 2007-10-17 WO PCT/FR2007/001703 patent/WO2008049994A1/fr not_active Ceased
  • 2007-10-17 KR KR1020097008314A patent/KR20090080948A/ko not_active Withdrawn
  • 2007-10-17 JP JP2009533896A patent/JP5431944B2/ja not_active Expired - Fee Related
  • 2007-10-17 EP EP07858463.8A patent/EP2078009B1/fr active Active
  • 2007-10-17 CA CA002664115A patent/CA2664115A1/fr not_active Abandoned
  • 2007-10-22 TW TW096139514A patent/TW200825083A/zh unknown
  • 2007-10-23 CL CL200703046A patent/CL2007003046A1/es unknown
  • 2007-10-23 AR ARP070104666A patent/AR063507A1/es unknown
  • 2007-10-24 PE PE2007001446A patent/PE20081261A1/es not_active Application Discontinuation
  • 2007-10-29 UY UY30667A patent/UY30667A1/es not_active Application Discontinuation
• 2009
  • 2009-03-13 TN TN2009000086A patent/TN2009000086A1/fr unknown
  • 2009-03-24 CR CR10690A patent/CR10690A/es not_active Application Discontinuation
  • 2009-04-05 IL IL197887A patent/IL197887A0/en unknown
  • 2009-04-24 CO CO09041714A patent/CO6160311A2/es unknown
  • 2009-05-18 MA MA31893A patent/MA30904B1/fr unknown
  • 2009-05-20 NO NO20091972A patent/NO20091972L/no not_active Application Discontinuation
  • 2009-11-24 US US12/625,005 patent/US8163750B2/en not_active Expired - Fee Related

Patent Citations (43)

Non-Patent Citations (67)

Also Published As

Similar Documents

Legal Events